Head-To-Head Review: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Titan Pharmaceuticals and Recursion Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals -328.67% -102.72% -70.99%
Recursion Pharmaceuticals -1,425.23% -73.43% -30.57%

Valuation & Earnings

This table compares Titan Pharmaceuticals and Recursion Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals $4.84 million 2.07 -$18.24 million N/A N/A
Recursion Pharmaceuticals $3.96 million 589.34 -$87.01 million N/A N/A

Titan Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals.

Institutional & Insider Ownership

3.9% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.4% of Recursion Pharmaceuticals shares are owned by institutional investors. 2.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Titan Pharmaceuticals and Recursion Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals 0 0 1 0 3.00
Recursion Pharmaceuticals 0 2 4 0 2.67

Titan Pharmaceuticals currently has a consensus target price of $11.00, indicating a potential upside of 989.11%. Recursion Pharmaceuticals has a consensus target price of $33.67, indicating a potential upside of 143.78%. Given Titan Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Titan Pharmaceuticals is more favorable than Recursion Pharmaceuticals.

Summary

Titan Pharmaceuticals beats Recursion Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.